Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Cristina Santos Vivas
Observed names:
C Santos Vivas,
C. Santos Vivas,
C. Santos-Vivas,
Cristina Santos-Vivas,
Cristina Santos‐Vivas,
Santos-Vivas, Cristina
show all 6
Institutions:
Instituto de Salud Carlos III,
Institut d'Investigació Biomédica de Bellvitge,
Institut Català d'Oncologia,
Duran i Reynals Hospital,
Centro de Investigación Biomédica en Red de Cáncer,
Universitat de Barcelona
show all 6
Observed institutions:
Institut Català d'Ornitologia,
Instituto de Salud Carlos III,
Institut d'Investigació Biomédica de Bellvitge,
Institut Català d'Oncologia,
Corporació Sanitària Parc Taulí,
Duran i Reynals Hospital,
Centro de Investigación Biomédica en Red de Cáncer,
Universitat de Barcelona
show all 8
ORCID:
0000-0002-9854-5097
Observed ORCID:
0000-0002-9854-5097
OpenAlex ID:
A5028818673
Works
52
Awards
1
LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients
2023
·
S. Lonardi
, F. Pietrantonio
, et al.
·
Annals of Oncology
·
60
PDF
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
2019
·
Johanna C. Bendell
, Tamara Sauri
, et al.
·
The Oncologist
·
49
PDF
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy
2019
·
J. Vidal
, B. Bellosillo
, et al.
·
Annals of Oncology
·
33
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis
2020
·
Andreas Schlicker
, Architha Ellappalayam
, et al.
·
International Journal of Cancer
·
28
PDF
511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial
2024
·
C. Santos Vivas
, J. Vidal Barrull
, et al.
·
Annals of Oncology
·
18
PDF
723O Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: Final results of the PEGASUS trial
2025
·
S. Marsoni
, M. Prisciandaro
, et al.
·
Annals of Oncology
·
16
LBA33 Circulating tumor (ct) DNA-guided anti-EGFR rechallenge strategy in metastatic colorectal cancer (mCRC): Final results of the phase II randomized CITRIC trial
2025
·
C. Montagut
, J. Vidal
, et al.
·
Annals of Oncology
·
16
P-118 Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study
2022
·
C. Santos Vivas
, F. Salva
, et al.
·
Annals of Oncology
·
9
New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients
2020
·
Jose Carlos Ruffinelli
, Cristina Santos Vivas
, et al.
·
Expert Review of Gastroenterology & Hepatology
·
4
Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients
2018
·
M. Martínez-Villacampa
, S. Besora Tavera
, et al.
·
Annals of Oncology
·
4
Tumor mutational burden as a determinant of metastatic dissemination patterns
2026
·
Eduardo Candeal
, Andrea Moreno‐Manuel
, et al.
·
Molecular Oncology
·
2
PDF
9P Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study
2024
·
R. Salazar Soler
, C. Santos Vivas
, et al.
·
Annals of Oncology
·
2
PDF
A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results
2018
·
G. Chiritescu
, K. Dumon
, et al.
·
Annals of Oncology
·
2
Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy
2018
·
J. Vidal
, A. Dalmeses
, et al.
·
Annals of Oncology
·
2
Are Gene Signatures Ready for Use in the Selection of Patients for Adjuvant Treatment?
2016
·
Cristina Santos Vivas
, Rebeca Sanz-Pamplona
, et al.
·
Current Colorectal Cancer Reports
·
2
Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection
2026
·
Andrei Kudriavtsev
, Saidi Daoud
, et al.
·
International Journal of Cancer
·
1
PDF
Definition of lines of treatment in metastatic colorectal cancer: a Delphi consensus
2025
·
Pilar García-Alfonso
, Julia Alcaide-Garcia
, et al.
·
Clinical & Translational Oncology
·
1
PDF
588P Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study
2024
·
V. Martelli
, J. Vidal Barrull
, et al.
·
Annals of Oncology
·
1
PDF
63O Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial
2024
·
E. Medico
, F.M. Buffa
, et al.
·
Annals of Oncology
·
1
130P Oxaliplatin immune-induced syndrome (OIIS): A potentially life-threatening complication in colorectal cancer (CRC) patients (pts)
2024
·
P. Vázquez-Revuelta
, J.C. Ruffinelli Rodriguez
, et al.
·
Annals of Oncology
·
1
PDF
408P Prediction of survival using the G8 scale frailty scale in a prospective series of elderly patients with colon cancer
2022
·
G. Soler Gonzalez
, L. Raventos
, et al.
·
Annals of Oncology
·
1
G8 screening tool for treatment decision-making in elderly colorectal cancer patients
2018
·
J. Marín
, G. Soler
, et al.
·
Annals of Oncology
·
1
Epidermal growth factor receptor (EGFR) as a prognostic factor over 10 years in non-metastasic colon carcinoma (NMCC)
2007
·
C. Pericay
, C. Santos-Vivas
, et al.
·
Journal of Clinical Oncology
·
1
Antimetastatic potential of NK cells in lung metastases across different cancer types
2026
·
Andrea Moreno-Manuel
, Eduardo Moreo
, et al.
·
Journal of Translational Medicine
100P Determinants of response to atezolizumab–bevacizumab (atezo–bev) in metastatic colorectal cancer (mCRC): Insights from the Motricolor CT3 trial
2026
·
C. Vaghi
, F.J. Ros Montana
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
52
Citation count:
255
H-index:
8
I10-index:
7
Year
Topic
Type